Transmucosal Fentanyl Products Become First Plug-and-Play REMS

When it comes to attempts to control misuse of fast-acting opioids, FDA’s intentions have backfired in the past. Success could point to a likely process for future class-wide REMS.

Laura Helbling

Transmucosal fentanyl products have become unlikely bellwethers of the REMS era.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Agency Leadership

More from Pink Sheet